Meet One of ASCO’s First Losers

By Chris Lange Updated Jan 6, 4:11AM EST · Published May 31, 12:00PM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Meet One of ASCO’s First Losers — © Sergey Tinyakov / Getty Images

Turning Point Therapeutics Inc. (NASDAQ: TPTX) shares dipped on Friday after the firm posted interim data for its midstage study in ROS1-positive non-small cell lung cancer patients. The data came from the firm’s ongoing Phase 1/2 Trident-1 clinical study of repotrectinib.

The results are being presented at the annual meeting of the American Society of Clinical Oncology (ASCO). They demonstrate ongoing antitumor activity and a manageable safety profile across multiple dose cohorts in both tyrosine kinase inhibitor (TKI) naïve and TKI-pretreated patients, including patients with intracranial disease.

A total of 83 patients were treated with repotrectinib at two different dose levels, and it was generally well tolerated. The most frequent treatment emergent adverse events (Grade 1 or 2) seen in patients were: dizziness (57%), dysgeusia (51%), dyspnea (30%), fatigue (30%), constipation (29%), paresthesia (29%) and anemia (28%). There were few Grade 3 treatment-related adverse events: (anemia (n=3); dizziness (n=2); and dyspnea, hypophosphatemia, hypoxia, pleural effusion and weight increase (all n=1), and no Grade 4 treatment-related adverse events or cases of dizziness leading to treatment discontinuation.

[nativounit]

Out of the total 83 patients, the preliminary efficacy analysis is for 33 patients. Forty-five percent of patients remained on treatment (15/33), with 12 of the 15 (80%) patients remaining on treatment for more than 12 months.

Dr. Byoung Chul Cho, Yonsei Cancer Center at Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, commented:

With additional follow up and new patients enrolled in the TRIDENT-1 study, repotrectinib continues to demonstrate promising efficacy and a safety profile consistent with a potential best-in-class ROS1 therapy for patients with advanced non-small cell lung cancer. The ongoing Phase 1 data remain encouraging in both TKI-naïve patients with intracranial disease and patients pretreated with crizotinib — including those with difficult to treat solvent front mutations — where there are currently very few therapeutic options.

Shares of Turning Point were down about 15% at $33.10 on Friday, in a 52-week range of $24.21 to $41.93. The consensus price target is $50.33.

[recirclink id=550873]
[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.